LRMR

Larimar Therapeutics, Inc.

7.28 USD
-0.85 (-10.46%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Larimar Therapeutics, Inc. stock is up 2.82% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 4 June’s closed higher than May. In the last 1 Unusual Options Trades, there were 1 CALL. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
16 May 17:37 17 May, 2024 7.50 CALL 6984 7087

About Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia.